Diabetes Drug And Accutane Block Breast Cancer Cell Growth, Cedars-Sinai Researchers Find

August 03, 1998

LOS ANGELES (July 21, 1998) -- Breast cancer cells exposed to a diabetes drug and the Vitamin A compound Accutane stopped multiplying and died on cue in laboratory and animal studies conducted at Cedars-Sinai Medical Center, researchers reported today in the journal Proceedings of the National Academy of Science.

Troglitazone, an antidiabetes drug, and Accutane, a Vitamin A compound used to treat severe acne, appear to work synergistically in permanently inhibiting cell growth and inducing apoptosis (programmed cell death) in breast cancer cells.

"Troglitazone alone has a mild effect on breast cancer cells. Accutane alone has a mild effect on breast cancer cells. Together, they have a dramatic effect," said Dr. H. Phillip Koeffler, Director of Hematology/Oncology at Cedars-Sinai Medical Center and Professor of Medicine at the University of California, Los Angeles.

Breast cancer cells stay young and vigorous, proliferating wildly while normal cells around them perform their functions, then mature and die as other cells replace them, Dr. Koeffler explained. The highly selective approach he and his team used not only deprives breast cancer cells of the protein energy source that makes them grow, but also programs them to age and die on schedule.

Importantly, the drug combination appears to have no adverse effect on healthy cells, either in laboratory studies or in immunodeficient mice injected with human breast cells that form tumors.

The way in which the drugs work is not fully understood, although their success is probably due to their targeting of distinct receptors on breast cancer cells that give them an edge over other cells, Dr. Koeffler said.

Troglitazone binds two receptors found in tumor cells: a steroid receptor called peroxisome proliferator-activated receptor gamma (PPARg), and a retinoid (Vitamin A) receptor. Accutane may then bind to this combined receptor. The activated receptor complex causes a protected gene within the cancer cell to be modulated.

That gene, bcl-2, is associated with programmed cell death. At high levels, it prevents cell death. At low levels, it induces cell death. "When exposed to the two-drug combination, cancer cells express almost undetectable levels of bcl-2," Dr. Koeffler said.

Since results of the in vitro (laboratory) and animal experiments were successful, preliminary research has begun to determine whether the drug combination is successful in humans. The first patient with prostate cancer has been enrolled in a study of troglitazone, and a small trial involving women with metastatic breast cancer will soon be underway.

New cancer drugs are often first tested on patients with advanced disease, explained Dr. Koeffler, since proved therapies exist for those with more treatable, early-stage cancer. If the results are promising in the most-difficult-to-treat patients, research begins on patients with less advanced disease, he said.
-end-
PLEASE NOTE: Contact David Schneier at Proceedings of the National Academy of Sciences , (202) 334-2138, for copies of the article, "Ligands for peroxisome proliferator-activated receptor-g and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice."

Contact Anita Roark in the Cedars-Sinai Health System Public Relations Department, (310) 855-4767 or (310) 855-4039, to arrange an interview with Dr. Phillip Koeffler.
-end-


Cedars-Sinai Medical Center

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.